| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/15/2004 | WO2004058239A1 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 07/15/2004 | WO2004058238A1 Use of cathepsin k inhibitors for the treatment of glaucoma |
| 07/15/2004 | WO2004058237A1 Therapeutic use of sibutramine and analogues thereof |
| 07/15/2004 | WO2004058236A1 Compositions and methods for treating upper respiratory congestion |
| 07/15/2004 | WO2004058235A2 Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative |
| 07/15/2004 | WO2004058234A2 Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
| 07/15/2004 | WO2004058233A1 Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate |
| 07/15/2004 | WO2004058229A1 Modified release formulations of selective serotonin re-uptake inhibitors |
| 07/15/2004 | WO2004058228A1 Enteric coated fluoxetine composition |
| 07/15/2004 | WO2004058221A1 Dosing aerosols containing lecithin as a surface-active substance |
| 07/15/2004 | WO2004058185A2 Antiangiogenesis by inhibiting protein kinase ck2 activity |
| 07/15/2004 | WO2004058176A2 Acyclic pyrazole compounds |
| 07/15/2004 | WO2004058170A2 Methods for treating malaria by modulation of g protein function |
| 07/15/2004 | WO2004058168A2 METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
| 07/15/2004 | WO2004058164A2 Asthma and allergic inflammation modulators |
| 07/15/2004 | WO2004058163A2 Pharmaceutical compositions and method of treating parkinson's disease |
| 07/15/2004 | WO2004058160A2 Compounds for the normalization of the sleep/wake cycle |
| 07/15/2004 | WO2004058159A2 Branched immunomodulatory compounds and methods of using the same |
| 07/15/2004 | WO2004058152A2 An extended release pharmaceutical composition of phenytoin sodium |
| 07/15/2004 | WO2004058151A2 Wound and skin care compositions |
| 07/15/2004 | WO2004058144A2 Antibacterial agents |
| 07/15/2004 | WO2004058143A2 High specificity anticancer pharmacological drug system, drug synthesis, and drug development process |
| 07/15/2004 | WO2004058141A2 An agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component |
| 07/15/2004 | WO2004058140A2 Non-pegylated long-circulating liposomes |
| 07/15/2004 | WO2004058139A2 Use of istradefylline (kw-6002) for the treatment of behavioral disorders |
| 07/15/2004 | WO2004058138A2 Oil composition based on peroxidised lipids, which can be used in the treatment of xerostomia |
| 07/15/2004 | WO2004058103A1 Method for treating patients for radiation exposure |
| 07/15/2004 | WO2004058048A2 Dehydroepiandrosterone (dhea) congeners for prevention and/or treatment of ulcers |
| 07/15/2004 | WO2004058042A2 Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases |
| 07/15/2004 | WO2004057983A1 Composition containing isoflavone of high purity at high concentration and process for producing the same |
| 07/15/2004 | WO2004057982A1 Food composition comprising a satiety enhancing amount of triacylglycerol and use in the manufacture of a medicament for the treatment or prevention of obesity |
| 07/15/2004 | WO2004057979A2 Dietary foodstuff for positively influencing cardiovascular health containing a carob product and an omega-3 fatty acid |
| 07/15/2004 | WO2004057966A1 Compositions and methods for control of bovine mastitis |
| 07/15/2004 | WO2004057950A2 Liposomal analgesic formulation and use |
| 07/15/2004 | WO2004052353A3 Aqueous-alcoholic depigmenting gel containing a phenolic derivative and a retinoid |
| 07/15/2004 | WO2004050621A3 Indol derivatives and their use as kinase inhibitors |
| 07/15/2004 | WO2004046334A3 Antioxidant and antimicrobial agents and methods of use thereof |
| 07/15/2004 | WO2004046320A3 METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF siRNAS OR CONSTRUCTS EXPRESSING siRNAS |
| 07/15/2004 | WO2004046109A3 Ionene oligomers and polymers |
| 07/15/2004 | WO2004045541A3 Soluble isoflavone compositions |
| 07/15/2004 | WO2004045536A3 Method and compositions for temporarily incapaciting subjets |
| 07/15/2004 | WO2004045528A3 Compositions and method for treating affective, painful or allergic disorders |
| 07/15/2004 | WO2004045505A3 Extract of stephaniae sinica diels and methods of using the same |
| 07/15/2004 | WO2004043443A3 Drugs for sexual dysfunctions |
| 07/15/2004 | WO2004043390A3 Pharmaceutical compositions and methods of using taxane derivatives |
| 07/15/2004 | WO2004043352A3 Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases |
| 07/15/2004 | WO2004043348A3 Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| 07/15/2004 | WO2004043342A3 Methods of treating injuries of the nervous system associated with hemorrhage |
| 07/15/2004 | WO2004041245A3 Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases |
| 07/15/2004 | WO2004041187A3 Compositions and methods for transdermal oxybutynin therapy |
| 07/15/2004 | WO2004041169A3 Modulation of cell fates and activities by phthalazine diones |
| 07/15/2004 | WO2004041158A3 Rifalazil compositions and therapeutic regimens |
| 07/15/2004 | WO2004039426A8 Transdermal delivery system for water insoluble drugs |
| 07/15/2004 | WO2004039328A3 Fludrocortisone treatment for hearing loss |
| 07/15/2004 | WO2004037373A3 CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE |
| 07/15/2004 | WO2004037190A3 Modified release compositions of milnacipran |
| 07/15/2004 | WO2004037159A3 Compounds, compositions and methods for modulating fat metabolism |
| 07/15/2004 | WO2004035738A3 Methylene-bridged selective androgen receptor modulators and methods of use thereof |
| 07/15/2004 | WO2004035736A3 Halogenated selective androgen receptor modulators and methods of use thereof |
| 07/15/2004 | WO2004035031A3 Treatment of uveal melanoma |
| 07/15/2004 | WO2004034987A3 Treatment for reactive arthritis or bursitis |
| 07/15/2004 | WO2004034978A3 Treating obesity with selective androgen receptor modulators |
| 07/15/2004 | WO2004032848A3 Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| 07/15/2004 | WO2004032708A3 Vasoregulating compounds and methods of their use |
| 07/15/2004 | WO2004030633A3 Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
| 07/15/2004 | WO2004028463A3 Methods and compositions for the treatment of lupus using clofarabine |
| 07/15/2004 | WO2004028453A3 Methods for preventing and treating obesity in patients with mc4 receptor mutations |
| 07/15/2004 | WO2004028442A3 Use of excipients to increase dna uptake by swine muscle cells |
| 07/15/2004 | WO2004028440A3 Vr1 antagonists for the treatment of urological disorders |
| 07/15/2004 | WO2004026260A3 Prophylactic and therapeutic hiv aptamers |
| 07/15/2004 | WO2004026248A3 Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| 07/15/2004 | WO2004026242A3 Substituted ketophosphonate inhibitors of tumor cell proliferation |
| 07/15/2004 | WO2004026218A3 Multi-use vessels for vitamin d formulations |
| 07/15/2004 | WO2004024130A3 TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE |
| 07/15/2004 | WO2004023340A9 Non-psychotropic cannabinoids for prevention of cognitive impairment |
| 07/15/2004 | WO2004019911A3 Buccal, polar or non-polar spray or capsule containing drugs for treating endocrine disorders |
| 07/15/2004 | WO2004017925A3 Methods and reagents for preventing bacteremias |
| 07/15/2004 | WO2004016211A3 Pi3k antagonists as radiosensitizers |
| 07/15/2004 | WO2004016100A3 Nutritional supplement for adolescents |
| 07/15/2004 | WO2004015089A3 Polyionic organic acid formulations |
| 07/15/2004 | WO2004014881B1 '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| 07/15/2004 | WO2004010927A3 Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes |
| 07/15/2004 | WO2004009026A3 Cholinergic therapy for individuals with learning disabilities |
| 07/15/2004 | WO2004005478A2 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 07/15/2004 | WO2004004714A1 Spirocyclic piperidines as mch1 antagonists and uses thereof |
| 07/15/2004 | WO2004002535A8 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 07/15/2004 | WO2003095625A3 Method for cytoprotection through mdm2 and hdm2 inhibition |
| 07/15/2004 | WO2003092715A3 Proteins involved in the regulation of energy homeostasis |
| 07/15/2004 | WO2003092626A3 Carvedilol pharmasolve solvate |
| 07/15/2004 | WO2003092613A3 Catechin multimers as therapeutic drug delivery agents |
| 07/15/2004 | WO2003092588A3 4-azasteroid derivatives as androgen receptor modulators |
| 07/15/2004 | WO2003088894A3 A multi component controlled release system for anhydrous cosmetic compositions |
| 07/15/2004 | WO2003087108A3 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses |
| 07/15/2004 | WO2003087040A3 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses |
| 07/15/2004 | WO2003086294A3 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| 07/15/2004 | WO2003080079B1 Use of sulfoalkyl ether cyclodextrin as a preservative |
| 07/15/2004 | WO2003078579A3 Compositions and methods for treating emphysema |
| 07/15/2004 | WO2003075852A3 Antibiotic composition |
| 07/15/2004 | WO2003075836A3 Cathepsin cysteine protease inhibitors |
| 07/15/2004 | WO2003070883A3 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |